Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771358 | 0.87 | HTT (0.54) | HTTSMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL2988553 | 0.83 | POLB (0.49) | HTTPOLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4060124 | 0.83 | POLB (0.49) | HTTPOLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL385728 | 0.82 | HTT (0.70) | HTTKMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL6766000 | 0.81 | LMNA (0.52) | HTTPOLBKMT2ASMN1; SMN2ALDH1A1 | |
| Methyl 2,3-Dimethoxybenzoate SCHEMBL311487 | 0.78 | GAA (0.66) | POLBKMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL6769548 | 0.78 | SMN1; SMN2 (0.47) | HTTPOLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7956411 | 0.78 | KMT2A (0.53) | HTTPOLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9774310 | 0.78 | POLB (0.57) | HTTPOLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1050558 | 0.77 | ALDH1A1 (0.49) | HTTKMT2ASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | HTT 3167/4885POLB 1620/4885KMT2A 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.